Home/Pipeline/PSG-301

PSG-301

Treatment-resistant Depression

PreclinicalActive

Key Facts

Indication

Treatment-resistant Depression

Phase

Preclinical

Status

Active

Company

PharmaSGP

About PharmaSGP

PharmaSGP is a clinical-stage biopharmaceutical company headquartered in Germany with a strategic focus on neurological and rare disease therapeutics. The company has built a diversified pipeline of novel drug candidates, primarily in Phase 2 development, targeting conditions such as Parkinson's disease, epilepsy, and rare genetic disorders. With a public listing providing financial stability, PharmaSGP combines scientific innovation with commercial execution to address complex medical challenges in specialized therapeutic areas.

View full company profile

Therapeutic Areas

Neurology Rare Diseases Central Nervous System

Other Treatment-resistant Depression Drugs

Drug	Company	Phase	Status
JNJ-1802	Johnson & Johnson	Phase 2	Active
DSP-6745	Sumitomo Pharma	Phase 1	Active
ML-104	MapLight Therapeutics	Preclinical	Lead optimization